1st Quarter - Report

THE SMITH-FREE GROUP, LLC for TEVA PHARMACEUTICALS USA, INC.

Period 1st Quarter 2022 Filed Apr 20, 2022 Signed by Jack S. Deuser, President & CEO

Official filing
Firm
THE SMITH-FREE GROUP, LLC
Client
TEVA PHARMACEUTICALS USA, INC.
Income
$80,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 2853 BLOCKING Act of 2021 (All sections of full text). H.R. 5376, Build Back Better Act (All sections of full text). S. 2910, Expanding Access to Low-Cost Generics Act of 2021 (All sections of full text). Discussions regarding S. 3799, PREVENT Pandemics Act of 2022. Discussions regarding the reauthorization of Generic Drug User Fee Amendments. Discussions regarding the approval of generic drugs. Discussions regarding improved education about digital health care. Monitored the implementation of P.L.117-7, To prevent across-the-board direct spending cuts, and for other purposes. Monitored Medicare and prescription drug changes.

LobbyistCovered position, as disclosed
JACK S DEUSER —
MICHAEL A. GAFFIN —
ROBERT HICKMOTT —
TREVOR W. KOLEGO —

Contacted: Centers For Medicare and Medicaid Services (CMS); Vice President of the U.S.; HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3799 (117th), S. 2910 (117th), H.R. 5376 (117th), H.R. 2853 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.